(NASDAQ: BFRI) Biofrontera's forecast annual revenue growth rate of 14.67% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Biofrontera's revenue in 2025 is $39,189,000.On average, 1 Wall Street analysts forecast BFRI's revenue for 2025 to be $433,992,221, with the lowest BFRI revenue forecast at $433,992,221, and the highest BFRI revenue forecast at $433,992,221. On average, 1 Wall Street analysts forecast BFRI's revenue for 2026 to be $478,799,677, with the lowest BFRI revenue forecast at $478,799,677, and the highest BFRI revenue forecast at $478,799,677.
In 2027, BFRI is forecast to generate $630,398,238 in revenue, with the lowest revenue forecast at $630,398,238 and the highest revenue forecast at $630,398,238.